Cas:1106871-37-7 1,4-Dioxaspiro[4.5]decane-8-boronic acid pinacol ester manufacturer & supplier

Chemical Name:1,4-Dioxaspiro[4.5]decane-8-boronic acid pinacol ester

CAS.NO:1106871-37-7

Synonyms:8-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1,4-dioxaspiro[4.5]decane;4,4,5,5-Tetramethyl-2-(1,4-dioxaspiro[4.5]decan-8-yl)-1,3,2-dioxaborolane;1,4-Dioxaspiro[4.5]decane,8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-;1,4-Dioxaspiro[4.5]decane-8-boronic acid pinacol ester

Molecular Formula:C₁₄H₂₅BO₄

Molecular Weight:268.15700

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:325.898ºC at 760 mmHg

Density:1.06

Index of Refraction:

PSA:36.92000

Exact Mass:268.18500

LogP:2.76590

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 8-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1,4-dioxaspiro[4.5]decane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,4-Dioxaspiro[4.5]decane-8-boronic acid pinacol ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,4-Dioxaspiro[4.5]decane,8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- Use and application,8-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1,4-dioxaspiro[4.5]decane technical grade,usp/ep/jp grade.

Related News: Elliott made its intention for a C-suite overhaul clear in an open letter early July. The activist investor called on GSK to appoint a new board directors with biopharma and consumer health expertise to select the leaders for the two companies. PhSiH(CH=CH)Hex2(αβ) manufacturers The $672 million raised in the listing will go toward expanding Stevanato’s factories in Italy and China and building a new plant for vials, syringes and cartridges in Fishers, Indiana—sweetened by $2.9 million in conditional tax credits from the state—that’s expected to bring more than 200 jobs to the area. 4,7,13,16,21,24-hexaoxabicyclo[8.8.8]hexacosane suppliers The suit says that while BRAF kinase inhibitors existed prior to Plexxikon’s discoveries, they were not selective, and Plexxikon’s have a core molecular structure that allows them to bind selectively to kinase created by the BRAF mutation. That allows for higher doses to be administered. 5,5-dimethyl-1,3-bis(phenylhydrazono)-2-(p-tolylhydrazono)cyclohexane vendor & factory.